StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Halozyme Therapeutics's total assets was $2.58B at Jun 30, 2026. For fiscal 2025 it was $2.53B, up 22.4% from the year before. Over ten years it grew 30.1% a year on average. The highest annual figure on record is $2.53B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.53B+22.4%
FY2024Dec 31, 2024$2.06B+19.1%
FY2023Dec 31, 2023$1.73B-5.9%
FY2022Dec 31, 2022$1.84B+66.7%
FY2021Dec 31, 2021$1.10B+90.4%
FY2020Dec 31, 2020$579.92M+2.5%
FY2019Dec 31, 2019$565.87M+28.5%
FY2018Dec 31, 2018$440.25M-15.3%
FY2017Dec 31, 2017$519.95M+98.8%
FY2016Dec 31, 2016$261.52M+43.9%
FY2015Dec 31, 2015$181.79M+9.5%
FY2014Dec 31, 2014$165.98M+63.1%
FY2013Dec 31, 2013$101.79M-24.4%
FY2012Dec 31, 2012$134.73M+104.9%
FY2011Dec 31, 2011$65.76M-28.0%
FY2010Dec 31, 2010$91.35M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.58B+25.5%
Q1 FY2026Mar 31, 2026$2.67B+21.7%
Q4 FY2025Dec 31, 2025$2.53B+22.4%
Q3 FY2025Sep 30, 2025$2.22B+4.9%
Q2 FY2025Jun 30, 2025$2.05B+4.3%
Q1 FY2025Mar 31, 2025$2.20B+19.3%
Q4 FY2024Dec 31, 2024$2.06B+19.1%
Q3 FY2024Sep 30, 2024$2.12B+11.9%
Q2 FY2024Jun 30, 2024$1.97B+8.8%
Q1 FY2024Mar 31, 2024$1.84B+8.4%
Q4 FY2023Dec 31, 2023$1.73B-5.9%
Q3 FY2023Sep 30, 2023$1.89B+1.5%
Q2 FY2023Jun 30, 2023$1.81B+1.6%
Q1 FY2023Mar 31, 2023$1.70B+46.2%
Q4 FY2022Dec 31, 2022$1.84B+66.7%
Q3 FY2022Sep 30, 2022$1.86B+57.3%
Q2 FY2022Jun 30, 2022$1.78B+73.6%
Q1 FY2022Mar 31, 2022$1.16B+20.2%
Q4 FY2021Dec 31, 2021$1.10B+90.4%
Q3 FY2021Sep 30, 2021$1.19B+126.2%
Q2 FY2021Jun 30, 2021$1.03B+94.7%
Q1 FY2021Mar 31, 2021$966.58M+96.3%
Q4 FY2020Dec 31, 2020$579.92M+2.5%
Q3 FY2020Sep 30, 2020$524.03M+41.5%
Q2 FY2020Jun 30, 2020$527.00M+26.1%
Q1 FY2020Mar 31, 2020$492.35M+14.7%
Q4 FY2019Dec 31, 2019$565.87M+28.5%
Q3 FY2019Sep 30, 2019$370.36M-16.7%
Q2 FY2019Jun 30, 2019$417.83M-12.0%
Q1 FY2019Mar 31, 2019$429.11M-13.4%
Q4 FY2018Dec 31, 2018$440.25M-15.3%
Q3 FY2018Sep 30, 2018$444.51M+24.5%
Q2 FY2018Jun 30, 2018$474.75M+37.7%
Q1 FY2018Mar 31, 2018$495.47M+118.5%
Q4 FY2017Dec 31, 2017$519.95M+98.8%
Q3 FY2017Sep 30, 2017$357.15M+26.4%
Q2 FY2017Jun 30, 2017$344.79M–
Q1 FY2017Mar 31, 2017$226.77M–
Q4 FY2016Dec 31, 2016$261.52M–
Q3 FY2016Sep 30, 2016$282.50M–

More Halozyme Therapeutics figures

See a number that looks wrong?